| Name | Title | Contact Details |
|---|---|---|
Michael Mayes |
Executive Director, Anti-Bribery and Anti-Corruption, Third Party and Distributor Compliance Lead | Profile |
Navicent Health was incorporated on November 17, 1994, as a nonprofit corporation whose primary purpose is to coordinate the Medical Center, Navicent Health and other affiliated entities in their mission of providing a comprehensive continuum of high quality, reasonably priced healthcare services to the region. Navicent Health has 830 beds for medical, surgical, rehabilitation and hospice purposes. The Medical Center, Navicent Health – a nationally recognized tertiary teaching hospital and the primary teaching hospital for Mercer University School of Medicine - includes but is not limited to: •Peyton Anderson Cancer Center, Navicent Health, a provider of comprehensive cancer care. Our services cover the continuum of cancer care, from screening and diagnosis through treatment and into survivorship. •Emergency Center, Navicent Health provides access to our Level 1 Trauma Center and includes helipad capability. The Emergency Center, along with our three urgent care locations, treat over 120,000 visitors per year. •Family Birth Center, Navicent Health has spacious labor and delivery suites, focuses on providing a family-friendly and family-centered environment for expectant mothers and their babies, and specializes in care for difficult pregnancies. •Heart Center, Navicent Health provides a full range of services for the prevention, diagnosis and treatment of cardiovascular disease, including congestive heart failure. •Rehabilitation Hospital, Navicent Health is the oldest and most experienced medical rehabilitation provider in central Georgia providing comprehensive services to help patients achieve their highest level of mobility and independence. •Beverly Knight Olson Children`s Hospital, Navicent Health, the region`s only dedicated pediatric hospital Navicent Health is the region`s leading provider of a comprehensive continuum of services. Whatever your healthcare needs, Navicent Health is here to assist you and your loved ones.
Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta`s collaboration with AbbVie, have now been approved around the world as part of AbbVie`s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta`s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).
Metabolic Solutions Development Company, LLC (MSDC) discovers and develops novel molecular targets and new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company has raised nearly $55 million in support of the development of its novel therapeutic drugs, MSDC-0160 and MSDC-0602, which selectively modulate mitochondrial control of to important cellular activities, such as carbohydrate, lipid, and amino acid metabolism, that are out of balance in patients with type 2 diabetes. Such imbalances may also play a role in other diseases of aging such as Alzheimer’s disease and Parkinson’s disease, as well certain genetic diseases such as polycystic kidney disease.
Zura Bio is a clinical stage biotechnology company focused on developing ZB 168, an anti IL7Rα inhibitor, for the treatment of alopecia areata and other inflammatory diseases.
University Cancer & Blood Center’s highly skilled medical professionals, whose backgrounds include working at the nation’s leading cancer centers, provide every patient with the...